George Jenkins Buys 4,000 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $131.51 on Wednesday. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -50.00 and a beta of -0.30. The stock’s 50-day moving average is $95.63 and its two-hundred day moving average is $81.70. Palvella Therapeutics, Inc. has a 1-year low of $18.23 and a 1-year high of $151.18.

Key Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Directors bought stock at the offering price, signaling insider confidence — Director Elaine Heron purchased 2,400 shares at $125/share (and George M. Jenkins also increased his stake). Insider buys can be viewed as management backing the company after the offering. Article Title
• Positive Sentiment: Palvella closed an upsized public offering that raised $230M (1,840,000 shares at $125, including full exercise of the underwriters’ option). The cash should extend runway and fund clinical programs (QTORIN rapamycin and pitavastatin), which reduces near‑term financing risk. Article Title
• Positive Sentiment: Analyst coverage remains constructive with multiple buy/strong-buy ratings and elevated price targets (consensus materially above current levels), which can support sentiment and provide a valuation anchor for investors. Article Title
• Neutral Sentiment: Market commentary is reassessing Palvella’s valuation after strong recent gains and a high price-to-book multiple — this is analysis-focused and may increase scrutiny but isn’t new company-specific news. Article Title
• Negative Sentiment: Share issuance is dilutive: the 1.84M new shares at $125 increases float and can create short-term selling pressure as the market absorbs supply. Some outlets flagged that reliance on offering proceeds underscores clinical-stage risk (no FDA approvals yet). Article Title

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. acquired a new stake in shares of Palvella Therapeutics during the third quarter worth about $21,255,000. Aspiriant LLC purchased a new position in Palvella Therapeutics during the 3rd quarter worth approximately $367,000. Aberdeen Group plc purchased a new position in Palvella Therapeutics during the 3rd quarter worth approximately $3,212,000. Frazier Life Sciences Management L.P. increased its position in Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Palvella Therapeutics in the second quarter valued at approximately $399,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on PVLA. Cantor Fitzgerald boosted their price target on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Craig Hallum began coverage on Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 target price on the stock. Truist Financial set a $210.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Mizuho upped their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $176.44.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.